Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Boston Scientific
(NY:
BSX
)
78.03
-13.59 (-14.83%)
Streaming Delayed Price
Updated: 2:41 PM EST, Feb 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Boston Scientific
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
These S&P500 stocks are the most active in today's session
↗
Today 14:05 EST
Via
Chartmill
Why Boston Scientific Stock Plummeted Today
↗
Today 13:21 EST
I'll be keeping a close eye on Boston Scientific stock following the market's peculiar reaction to its solid earnings report.
Via
The Motley Fool
Boston Scientific (BSX) Earnings Transcript
↗
Today 13:16 EST
Boston Scientific (BSX) Earnings Transcript
Via
The Motley Fool
Wednesday's session: top gainers and losers in the S&P500 index
↗
Today 12:35 EST
Via
Chartmill
Why Boston Scientific (BSX) Shares Are Getting Obliterated Today
Today 12:25 EST
Shares of medical device company Boston Scientific (NYSE:BSX) fell 13.9% in the afternoon session after the company reported fourth-quarter 2025 results that beat Wall Street estimates but provided a...
Via
StockStory
BSX Stock Tumbles Pre-Market On Softer 2026 Sales Growth Forecast
↗
Today 7:46 EST
Via
Stocktwits
Boston Scientific Corp (NYSE:BSX) Stock Plummets 9% Despite Mixed Q4 2025 Earnings
↗
Today 7:24 EST
Via
Chartmill
Gapping S&P500 stocks in Wednesday's session
↗
Today 10:35 EST
Via
Chartmill
Boston Scientific Stock Hits 52-Week Low On Soft 2026 Outlook
↗
Today 10:03 EST
Boston Scientific Corporation (NYSE: BSX) reported Q4 2025 revenues of $5.29B, beating management guidance and consensus estimate.
Via
Benzinga
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
↗
Today 8:35 EST
Via
Chartmill
Boston Scientific (NYSE:BSX) Reports Q4 CY2025 In Line With Expectations
Today 6:40 EST
Medical device company Boston Scientific (NYSE:BSX) met Wall Streets revenue expectations in Q4 CY2025, with sales up 15.9% year on year to $5.29 billion. The company expects next quarter’s revenue to...
Via
StockStory
Earnings To Watch: Boston Scientific (BSX) Reports Q4 Results Tomorrow
February 02, 2026
Medical device company Boston Scientific (NYSE:BSX) will be announcing earnings results this Wednesday before the bell. Here’s what you need to know.
Via
StockStory
Topics
Artificial Intelligence
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
February 02, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Boston Scientific’s $14.5 Billion Stroke of Genius: Consolidation Heats Up in the Medtech Arms Race
February 02, 2026
In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The...
Via
MarketMinute
Topics
Artificial Intelligence
3 Market-Beating Stocks with Exciting Potential
January 28, 2026
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends...
Via
StockStory
Boston Scientific to Acquire Penumbra for $14.5 Billion in Massive MedTech Consolidation
January 28, 2026
MARLBOROUGH, Mass. — In a move that has sent shockwaves through the medical technology landscape, Boston Scientific (NYSE: BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra...
Via
MarketMinute
The $14.5 Billion Clot-Bust: Boston Scientific’s Bold Bet on Penumbra Signals a New Era of Medtech Giants
January 27, 2026
In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced on January 15, 2026, its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN)...
Via
MarketMinute
S&P 500 Hits Record Highs as Tech Earnings Ignite Market Rally
January 27, 2026
The U.S. stock market reached a historic milestone on January 27, 2026, as the S&P 500 (NYSEARCA:SPY) climbed to a fresh all-time high of 6,980.75, tantalizingly close to the psychologically...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
The Great Consolidation: US M&A Values Double as AI and Bio-Pharma Spark $2 Trillion Surge
January 26, 2026
As of January 26, 2026, the American corporate landscape is undergoing its most radical transformation in a generation. Following a two-year period of high-interest-rate hibernation, the United States...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Johnson & Johnson 2026 Outlook: Chasing the $100 Billion Milestone Amidst Legal and Patent Hurdles
January 23, 2026
Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released...
Via
MarketMinute
Topics
Artificial Intelligence
Bankruptcy
Economy
Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026
January 23, 2026
As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...
Via
MarketMinute
Topics
Artificial Intelligence
Bankruptcy
Economy
1 of Wall Street’s Favorite Stock with Promising Prospects and 2 We Find Risky
January 22, 2026
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...
Via
StockStory
Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth
January 22, 2026
NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the...
Via
MarketMinute
Topics
Earnings
Economy
Intellectual Property
Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat
January 22, 2026
Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an...
Via
MarketMinute
Topics
Earnings
Economy
The Titan’s Balance: Johnson & Johnson Reaches Record Highs Amidst Legal Hurdles and Med-Tech Transformation
January 20, 2026
As the healthcare industry looks toward 2026, Johnson & Johnson (NYSE: JNJ) stands at a historic crossroads, reinforcing its reputation as the ultimate bellwether for the global healthcare sector. On...
Via
MarketMinute
Topics
Bankruptcy
Lawsuit
World Trade
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
January 20, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Stay informed with the top movers within the S&P500 index on Tuesday.
↗
January 20, 2026
Via
Chartmill
"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape
January 15, 2026
As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
Exploring the top movers within the S&P500 index during today's session.
↗
January 15, 2026
Via
Chartmill
Why Boston Scientific (BSX) Stock Is Down Today
January 15, 2026
Shares of medical device company Boston Scientific (NYSE:BSX) fell 4.6% in the afternoon session after the company agreed to acquire Penumbra in a transaction valued at approximately $14.5 billion,...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.